Breast cancer
CTD - Clinical Trials Data
Abbreviations
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Pembrolizumab for Early Triple-Negative Breast Cancer
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer
© 2021 - 2024 | MedAgora Consulting srl